x
11/2020 team

WELCOME MIRCO

OCCIDENT welcomes Mirco Müller as new Investment Analyst for the life sciences sector at the Zug office. Mirco studied chemistry and economics at the University of Freiburg in Germany and spent a semester abroad in Singapore. He gained professional experience in the research and development of novel material systems. At OCCIDENT, Mirco supports the comprehensive analysis and due diligence of new investment opportunities.

11/2020 About

OCCIDENT IN THE VENTURE CAPITAL MAGAZINE

“Strong companies are shaped by entrepreneurs and not by investors”, our CEO Patrizia Schützenhöfer is quoted in the special edition Start-up 2021 of Venture Capital Magazine. Which manifold added value investors can bring into start-ups besides capital and how valuable a good fit in a consortium is, gets explained in the corresponding article.

Issue 07/2020 from page 40 (only available in German language)

10/2020 Portfolio

FOLLOW-UP INVESTMENT IN ADIVO

adivo, our portfolio company in the field of veterinary medicine, convinced us for a second time to invest in the promising technology and the highly motivated team together with High-Tech Gründerfonds. The current funding will be used to continue the company’s own projects, expand the successful partnering and enlarge the team.

More about adivo

09/2020 About

OCCIDENT FEATURED IN THE PLATTFORM LIFE SCIENCES

We definitely “dare” – with almost 50% of our life sciences investments in the biotech sector, we are absolutely convinced of its success potential, innovative strength and impact. How our CEO, Patrizia Schützenhöfer, assesses the current situation of venture capital in biotech and how OCCIDENT invests in this field, can be found in the latest issue of the Plattform Life Sciences.

Issue 03/2020 from page 134 (only available in German language)

09/2020 About

OCCIDENT INVESTS IN DEEP TECH

As a deep tech investor, we are pleased to be perceived as such by the University of Zurich. OCCIDENT is one of the most active investors in life sciences spin-offs from Swiss universities, which account for almost one third of our portfolio. Together with our German spin-offs, almost two thirds of our start-ups’ technologies were developed at universities or research institutions. For us, this once again demonstrates the great potential of excellent research in Switzerland and Germany.

Read more

09/2020 Portfolio

TOP 100 SWISS STARTUP AWARD 2020

Just like in 2019, we congratulate three of our portfolio companies on their placements among this year’s TOP 100 Swiss Startup Award – two of them even made it into the TOP 8. Congratulations to Versantis, Resistell and hemotune for their ranking as 3 of the most promising start-ups in Switzerland. OCCIDENT is proud to have these aspiring start-ups in its portfolio.

More about Versantis

More about Resistell

More about hemotune

09/2020 About

NEW ADDRESS IN MUNICH

Growth needs space that’s why we are moving with our Munich team into our own and bigger offices near the Gärtnerplatz. We are very much looking forward to welcoming our portfolio companies, further team members and business partners and to meeting highly motivated founders in the Isarvorstadt.

08/2020 team

WELCOME SIMON

OCCIDENT welcomes Simon Schild von Spannenberg as new Junior Investment Manager for the high-tech sector at the Munich office. Simon studied Industrial Engineering (Mechanical Engineering) as well as Energy Science and Engineering at the Technical University of Darmstadt and spent a semester abroad in Nicaragua. Afterwards he gained experience as a founder and in the field of M&A with a focus on Cleantech. At OCCIDENT, Simon is responsible for deal sourcing and building a high-tech start-up portfolio.

08/2020 Portfolio

INVESTMENT IN HEMOTUNE

For the third month in a row, we are proud to welcome a new venture to our portfolio. OCCIDENT acted as lead investor for the Series A of the Swiss start-up hemotune, which developed HemoSystem, a groundbreaking platform technology for extra­corporeal blood purification. This technology uses magnetic nanoparticles to purify the blood of previously inaccessible pathogenic biomolecules and toxins. The primary applications are sepsis and septic shock, the consequences of which up to 6 million people die every year according to the WHO.

More information can be found in the press release under the following link.

More about hemotune

Show more